Invivyd Reports Positive Phase 3 LIBERTY Data for VYD2311
NEW HAVEN, Conn. — September 29, 202 Invivyd announced topline results from the Phase 3 LIBERTY study evaluating VYD2311,...
prophylaxis
Advertisement
Novo Nordisk Gains Positive CHMP Opinion for FREHEMGO
BAGSVAERD, Denmark — September 17, 2026 Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP)...
ENA Respiratory Advances INNA-051 Into Part B Phase IIa
MELBOURNE, Australia — September 15, 2026 ENA Respiratory announced that the first participants have been dosed in Part B...
Octapharma USA Expands FDA Approval for wilate® in Children
PARAMUS, N.J. | July 8, 2026 Octapharma USA has announced that the U.S. Food and Drug Administration (FDA) has...
Pharvaris Unveils Breakthrough Oral Therapy for HAE Relief
ZUG, Switzerland, November 10, 2025 — Pharvaris N.V. (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor...
Advertisement
